367 related articles for article (PubMed ID: 31693129)
1. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
2. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
6. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
7. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
8.
Paterson AHG; Lucas PC; Anderson SJ; Mamounas EP; Brufsky A; Baez-Diaz L; King KM; Lad T; Robidoux A; Finnigan M; Sampayo M; Tercero JC; Mairet JJ; Wolff AC; Fehrenbacher L; Wolmark N; Gomis RR
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377934
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Palmieri C; Fullarton JR; Brown J
Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
[TBL] [Abstract][Full Text] [Related]
12. Role of Bisphosphonates in Breast Cancer Therapy.
Goldvaser H; Amir E
Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
[TBL] [Abstract][Full Text] [Related]
15. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Paterson AH; Anderson SJ; Lembersky BC; Fehrenbacher L; Falkson CI; King KM; Weir LM; Brufsky AM; Dakhil S; Lad T; Baez-Diaz L; Gralow JR; Robidoux A; Perez EA; Zheng P; Geyer CE; Swain SM; Costantino JP; Mamounas EP; Wolmark N
Lancet Oncol; 2012 Jul; 13(7):734-42. PubMed ID: 22704583
[TBL] [Abstract][Full Text] [Related]
16. The role of bisphosphonates in early breast cancer.
Paterson AH
Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
[TBL] [Abstract][Full Text] [Related]
17. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.
Mauri D; Valachis A; Polyzos IP; Polyzos NP; Kamposioras K; Pesce LL
Breast Cancer Res Treat; 2009 Aug; 116(3):433-9. PubMed ID: 19521766
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
20. Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Vliek SB; Noordhoek I; Meershoek-Klein Kranenbarg E; van Rossum AGJ; Dezentje VO; Jager A; Hokken JWE; Putter H; van der Velden AWG; Hendriks MP; Bakker SD; van Riet YEA; Tjan-Heijnen VCG; Portielje JEA; Kroep JR; Nortier JWR; van de Velde CJH; Linn SC
J Clin Oncol; 2022 Sep; 40(25):2934-2945. PubMed ID: 35442755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
